Dr. Ravi Parikh, a noted ophthalmologist in New York, was recently awarded one of the highest recognitions from the American Society of Retina Specialists, ASRS, at its annual conference in July 2023.
The ASRS presented Dr. Parikh the 2023 Honor Award “For Outstanding Service to the Society’s Scientific and educational Programs, Original Papers, Panel Discussions, Instructional Courses.”
A Board-Certified Ophthalmologist Dr. Parikh of Manhattan Retina and Eye is a retina specialist whose goal is to combine clinical medicine, health policy, management, and to better deliver care to patients in the U.S. and abroad, is known for his forward looking approach to care, including using artificial intelligence and spreading awareness about telemedicine. Dr. Parikh received his medical training at Vanderbilt University and earned a Masters of Public Health in Policy and Management from Harvard University. He trained as a resident at Yale University School of Medicine/Yale Eye Center/Yale New Haven Hospital.
He has been the Director of Healthcare Delivery Research, Department of Ophthalmology, NYU Grossman School of Medicine/NYU Langone Health. His hospital appointments include New York University Langone Health 2019; Bellevue Hospital, New York Health and Hospitals Corporation New York, 2019; and Mount Sinai Hospital New York, NY, 2019.
Dr. Parikh is a member of the American Academy of Ophthalmology’s Health Policy Committee and the American Society of Retina Specialists’ Federal Affairs Committee.
At the ASRS 2023 meeting, Dr. Parikh spoke on the issue “Biosimilar Paradox: How Biosimilar Use Will Increase Patient and Healthcare Cost.”
“Great American society of retinal specialists meeting. Happy to see friends, learn a lot, and present on the biosimilar paradox and how we will need to advocate to make sure our patients have access to low cost repackaged bevacizumab. Also humbled to get the ASRS honor award!,” Dr. Parikh is quoted saying on Linkedin.
He has published numerous papers in top journals such as Ophthalmology and JAMA ophthalmology and his work has been cited in Bloomberg Businessweek (https://www.bloomberg.com/news/articles/2020-10-28/how-private-equity-helped-corner-the-cancer-care-market-in-naples-florida) as well as Wired Magazine (the leading technology magazine in the United States https://www.wired.com/story/us-government-pay-doctors-use-ai-algorithms/).
After finishing his fellowship, Dr. Parikh went on to publish numerous studies in Ophthalmology and JAMA Ophthalmology (the two leading ophthalmic research journals) while running his own practice (Manhattan Retina and Eye Consultants) along with studies in numerous other journals.
His work (almost all of which he has led the study as corresponding author) has included several firsts such as the first and largest evaluation of national anti-VEGF use over 10 years and across all diagnoses (published in ophthalmology), the first global use of anti-VEGF across the US, UK, Australia, and Asia (published ophthalmology retina), the largest study evaluating surgical errors in ophthalmology and how to improve/reduce errors (published in Ophthalmology), the first study to describe medical malpractice cases D ophthalmic trainees (published in Ophthalmology), the first study showing the increase of and trend of private equity acquisitions in ophthalmology (published in Ophthalmology), the first study assessing telemedicine usage before and after COVID 19 beyond a single institution (published in Ophthalmology), and the first study demonstrating economic/reimbursement challenges in using artificial intelligence to identify diabetic retinopathy (published in Ophthalmology and featured in Wired Magazine).